Brind.

Goldman Sachs supported a 'Buy' rating for Iovance Biotherapeutics based on positive Amtagvi data.

1 report, 0 independent Updated Jun 29

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Iovance Biotherapeutics Goldman Sachs

Keep exploring

The entities involved

Iovance Biotherapeutics
American biopharmaceutical startup

Nothing else this week.
Goldman Sachs
American investment bank
- US-Iran truce aims to reopen Strait of Hormuz amid global monetary policy shifts and oil price drops.Mon 17:37
- Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24

Coverage

Newest first; wire copies grouped

Jun 29Unknown outlet